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Abstract
Pancreatic cancer is characterized by a high degree of resistance to chemotherapy. Epidermal growth factor
receptor (EGFR) inhibition using the small-molecule inhibitor erlotinib was shown to provide a small survival benefit
in a subgroup of patients. To identify kinases whose inhibition acts synergistically with erlotinib, we employed a
kinome-wide small-interfering RNA (siRNA)-based loss-of-function screen in the presence of erlotinib. Of 779 tested
kinases, we identified several targets whose inhibition acted synergistically lethal with EGFR inhibition by erlotinib,
among them the S6 kinase ribosomal protein S6 kinase 2 (RPS6KA2)/ribosomal S6 kinase 3. Activated RPS6KA2
was expressed in approximately 40% of 123 human pancreatic cancer tissues. RPS6KA2 was shown to act down-
stream of EGFR/RAS/mitogen-activated protein kinase kinase (MEK)/extracellular-signal regulated kinase (ERK)
signaling and was activated by EGF independently of the presence of KRAS mutations. Knockdown of RPS6KA2
by siRNA led to increased apoptosis only in the presence of erlotinib, whereas RPS6KA2 activation or overexpres-
sion rescued from erlotinib- and gemcitabine-induced apoptosis. This effect was at least in part mediated by down-
stream activation of ribosomal protein S6. Genetic as well as pharmacological inhibition of RPS6KA2 by the inhibitor
BI-D1870 acted synergistically with erlotinib. By applying this synergistic lethality screen using a kinome-wide RNA
interference–library approach, we identified RPS6KA2 as potential drug target whose inhibition synergistically
enhanced the effect of erlotinib on tumor cell survival. This kinase therefore represents a promising drug candidate
suitable for the development of novel inhibitors for pancreatic cancer therapy.
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Introduction
Pancreatic cancer is associated with the worst prognosis of all solid
tumors [1] and is characterized by a largely drug-resistant phenotype.
Histologically, the majority of pancreatic cancers are ductal adeno-
carcinomas that frequently express high levels of the epidermal growth
factor receptor (EGFR) [2]. EGFR-dependent signaling cascades lead
to enhanced cell cycle progression, cell growth, angiogenesis, and sur-
vival. To date, inhibition of the EGFR pathway by the small-molecule
inhibitor erlotinib represents the only targeted therapy approved for
metastatic pancreatic ductal adenocarcinoma [3]. This approval was
based on a clinical trial demonstrating a significant survival benefit
in patients receiving erlotinib in combination with gemcitabine
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compared to patients treated with gemcitabine plus placebo [4]. The
benefit, however, is only marginal for the majority of patients. Inter-
estingly, a subgroup of patients that develops a skin rash as side effect
of erlotinib therapy seems to have a clinically more significant survival
advantage [4]. The underlying molecular mechanism behind this
observation remains to be fully elucidated [5]. Moreover, it is not
entirely clear at this point whether the erlotinib-induced rash is pre-
dictive of treatment response to erlotinib or serves merely as a prog-
nostic factor reflecting a more favorable tumor biology [5].
It is evident that the efficacy of erlotinib in combination with
gemcitabine is clinically not satisfying and restricted to only a small
subgroup of patients. Identifying additional targets whose inhibition
might act synergistically with erlotinib thereby providing a substan-
tial benefit for a larger group of patients is crucial to improve the
devastating prognosis of pancreatic cancer.
Screening approaches to identify novel target proteins with func-
tional impact on cardinal hallmarks of cancer such as tumor cell sur-
vival, invasiveness, and proliferation are essential to identify novel
targets in an unbiased manner. Loss-of-function screens based on
RNA interference (RNAi) libraries represent a powerful tool to identify
new potential therapeutically relevant targets in this context [6,7].
Synthetic lethality screens aim to identify targets whose knockdown acts
synergistically with another compound or a distinct genetic state [6].
Ribosomal S6 kinases (RSKs) represent a family of serine/threonine
protein kinases with a molecular weight of 90 kDa. RSK was first
discovered in Xenopus by Erikson and Maller who also identified
the ribosomal protein S6 (rpS6) as physiological target of RSK [8].
To date, the RSK family comprises four members (RSK1 to RSK4)
[9]. RSK1 and RSK2 have been described to mediate cell survival,
motility, and proliferation [10,11]. RSK3, also known as ribosomal
protein S6 kinase 2 (RPS6KA2), has been implicated in cell cycle pro-
gression [12]. In ovarian cancer, however, it has been reported that
RSK3 may act as a tumor suppressor [13]. The RSK3 gene is located
on chromosome 6q27 and highly expressed in lung, heart, muscle,
and brain [9]. The RSK3 protein is composed of 733 amino acids
and contains two functional domains, a carboxyl-terminal kinase
domain and an amino-terminal kinase domain. RSK3 is activated by
EGF-dependent signaling pathways through mitogen-activated protein
kinase kinase/extracellular-signal regulated kinase (MEK)/(ERK)
[12,14] and localized in its inactive form in the cytoplasm. Following
activation, RSK3 is localized in the nucleus. In quiescent cells, RSK3
forms a complex with ERK1/2 [15,16]. On activation, the RSK-ERK
complex shifts to the nucleus. RSK1 and RSK2 are also able to form a
complex with ERK1 or ERK2, but on activation, the complex is disso-
ciating, which could be the reason why RSK3 has a longer activation
period compared to other isoforms [15,16].
The aim of this study was to identify targets acting synergistically
with the EGFR inhibitor erlotinib. For this purpose, we performed a
kinome-wide RNAi-based loss-of-function screen in the presence of
erlotinib. Among the screen hits, we identified and characterized RSK3
as a promising druggable candidate gene whose inhibition synergis-
tically enhanced the efficacy of erlotinib in pancreatic cancer cells.
Materials and Methods
Cell Culture
PaTu 8988t pancreatic cancer cells were obtained from the German
Collection of Cell Lines [Deutsche Sammlung von Mikroorganismen
und Zellkulturen (DSMZ), Braunschweig, Germany]. BxPC-3, PANC-1,
Capan-1, and HPDE cells were from the American Type Culture
Collection (Rockville, MD). IMIM-PC-1 cells and Suit-2-007 cells
were kind gifts from Dr F. X. Real [Centro Nacional de Investigaciones
Oncológicas (CNIO),Madrid, Spain] and Takeshi Iwamura (Miyazaki,
Japan), respectively. BxPC-3 cells were cultured in RPMI 1640
medium (PAA, Cölbe, Germany) supplemented with 10% FBS
(PAA). PaTu8988t and IMIM-PC-1 cells weremaintained inDulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA), also supple-
mented with 10% FBS. Stably transfected BxPC-3 and PaTu8988t
cell clones were grown under the same conditions as the parental cell
line with addition of G418 (PAA). All cells were grown at 5% CO2
and 37°C.
The Kinome RNAi Library Screen
For the screen, we used the Dharmacon (Thermo Fisher Scientific,
Waltham, MA) whole-kinome RNAi library comprising 779 kinases.
BxPC-3 cells were seeded into 96-well plates (7000 per well). Transfec-
tion with four pooled independent silencing sequences per gene was
carried out in quadruplicate 1 day later according to the manufacturer’s
instructions (Dharmacon), using DharmaFECT 1 (Dharmacon) as the
transfection reagent and an small interfering RNA (siRNA) concen-
tration of 20 nM per well. Forty-eight hours after transfection, erlotinib
(10 μM) or solvent was added. After incubating for another 48 hours,
cell viability was measured using the CellTiter-Glo Assay from Promega
(Fitchburg, WI) according to the manufacturer’s instructions. As
controls, we used scrambled nonsilencing siRNAs. Effects on cell via-
bility of individual siRNAs were calculated as logarithmic z values
and were normalized to the mean cell viability of all transfected wells.
Three independent experiments were performed, and only targets who
showed consistent results in all three runs were further validated. The
complete data set of the RNAi kinome screen comprising 799 kinases
is depicted in Table W1.
siRNA Transfection and Plasmids
Pooled and individual siRNA sequences for target validation as
well as transfection reagents were obtained from Dharmacon. The
transfection was carried out using the wet reverse transfection proto-
col from Dharmacon using an siRNA concentration of 25 nM. For
overexpression experiments, we transfected pWZL-Neo-myr-flag/
Dest and pWZL-Neo-myr-flag/RPS6KA2 plasmids from Addgene
(Cambridge, MA) using the transfection reagent TransFast from
Promega according to the manufacturer’s instructions. For genera-
tion of stable single-cell clones, cells were seeded as single cells into
96-well plates and treated with G418 (400 μg/ml for BxPC-3 and
800 μg/ml for PaTu-8988t cells) for 2 weeks.
Reagents
The Mek1/2 inhibitor UO126 was obtained from Merck KGaA
(Darmstadt, Germany), the phosphatidylinositol-4,5-bisphosphate 3 (PI3)
kinase inhibitor LY294002 from Cell Signaling Technology (Danvers,
MA), the EGFR inhibitor erlotinib fromLCLaboratories, Inc (Woburn,
MA), and the RSK inhibitor BI-D1870 from Enzo Life Sciences GmbH
(Lörrach, Germany). Human recombinant EGF was purchased from
R&D Systems (Minneapolis, MN). After culturing cells in serum-
free medium for 24 hours, the inhibitors were added for 2 hours,
and then EGF (5 ng/ml) was added for 15 minutes. Samples were
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lysed in buffer containing protease and phosphatase inhibitors (Roche,
Basel, Switzerland).
Western Blot Analysis
Protein concentration was estimated using the Bradford method.
Ten micrograms of protein sample was loaded on a 10% acrylamide
gel and blotted on polyvinylidene fluoride (PVDF) membranes. The
blocking reagent was 5% nonfat milk powder disolved in 0.1% tris-
buffered saline supplementedwith 0.1%Tween 20 (TBST), and primary
antibodies were dissolved according to the manufacturer’s instructions
and incubated overnight at 4°C. Antibodies for pERK1/2, ERK1/2,
pRSK3 (T356/S360), prpS6 (S235/236), rpS6, RSK1, RSK2, EGFR,
and poly(ADP-ribose) polymerase (PARP) were obtained from Cell
Signaling Technology, pRSK3 (S218) from R&D Systems, RSK3
and KRAS from Abcam (Cambridge, United Kingdom), and β-Actin
from Sigma-Aldrich (St Louis, MO). The secondary anti-rabbit anti-
body was diluted in 5% skim milk and 1% TBST (1:10,000) and
incubated for 1 hour at room temperature (RT). The ECL Substrate
(PerkinElmer, Waltham, MA) and the digital imaging system from
Intas (Göttingen, Germany) were used for visualization. Specificity of
the RSK antibodies was confirmed by siRNA experiments (FigureW1).
Functional Assays
Cell viability was determined by using 5 mg/ml thiazolyl blue,
which was incubated in serum-free medium for 1 hour at 37°C.
Subsequently, cells were lysed (10% Triton X-100 with 0.1 M HCl in
isopropanol) and measured in a photometer (Thermo Fisher Scientific,
Waltham, MA) at 570 nm. Apoptosis was measured using a DNA frag-
mentation assay (Roche) according to the manufacturer’s instructions or
by Western blot analysis of PARP cleavage. Proliferation was deter-
mined with the bromodeoxyuridine (BrdU) cell proliferation kit
(Roche) according to the manufacturer’s instructions.
Immunohistochemistry
Immunohistochemistry was performed [17] using the ABC standard
staining protocol. Human pancreatic cancer tissues were analyzed
using a multiple tissue array (MTA), which contains 548 tissue sam-
ples from 123 patients with available clinical follow-up data. Tissues
were collected according to the guidelines of the local ethics com-
mittee of the Technical University of Dresden. Murine pancreatic
cancer tissues and normal pancreata were derived from KPC mice
(LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx1-Cre) for immunohisto-
chemical analysis.
Statistical Analysis
Statistical analyses were performed using the Tukey-Kramer test
for multiple comparisons. P values <.05 were considered significant.
Data are presented as means ± SD and are representative for at least
three independent experiments.
Results
Kinome-Wide Loss-of-Function Screen
To identify target genes whose knockdown would affect cell via-
bility synergistically with erlotinib, we employed a whole-kinome
siRNA library comprising 779 kinases. The pancreatic cancer cell
line BxPC-3 was transfected with pooled siRNAs (four silencing
sequences per gene), and the impact of the knockdown of each gene
on cell viability was assessed in the presence of erlotinib. The 12 top
genes whose knockdown significantly decreased cell viability are
summarized in Table W1.
Subsequently, 9 of the 12 top screen hits could be validated indi-
vidually by using four independent silencing sequences per gene com-
pared to nonsilencing controls (Figure 1). Among the targets were
several well-known modulators of tumor progression such as drivers
of cell cycle progression [mitogen-activated protein kinase kinase
kinase 3 (MAP3K3) and MAP3K2], DNA damage–associated check-
point control [checkpoint kinase1 (CHEK1)], and cytokine signaling
Janus kinase 2 ( JAK2; Figure 1]. The two proteins whose knock-
down had the greatest impact on cell viability on individual validation
were MAP3K3, also known as MEK kinase 3, and RPS6KA2, also
known as p90 ribosomal S6 kinase RSK3. Because information on
the impact of RPS6KA2/RSK3 in cancer is rudimentary, we focussed
on RPS6KA2/RSK3 for further validation and characterization.
To elucidate the role of RSK3 in pancreatic cancer, we first examined
expression levels in various pancreatic cancer cell lines (Figure 2A).
RSK3 protein was expressed in all examined cell lines to various extents.
RSK3 is phosphorylated at several serine or threonine residues leading
to its activation. Phosphorylation of both major phosphorylation sites
Figure 1. Target validation of the RNAi screen results. Cell viability in BxPC-3 cells was determined in the presence of erlotinib after
knockdown of the individual target genes using four independent silencing sequences or scrambled nonsilencing control siRNAs (siC).
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Thr356/Ser360 and Ser218 could be detected at varying levels in all cell
lines by phospho-specific antibodies (Figures 2A and W2).
Interestingly, BxPC-3 cells that had been used in the RNAi screen
showed relatively low expression levels of RSK3 protein, although
phosphorylation at both Thr356/Ser360 and Ser218 sites could be readily
detected. We therefore decided to use two pancreatic cell lines, BxPC-3
and additionally PaTu-8988t, which exhibits high basal RSK3 expres-
sion levels, for further validation experiments. Moreover, PaTu-8988t
cells harbor an activating KRAS mutation, whereas wild-type KRAS is
found in BxPC-3 cells. This is particularly important because RSK3 is
activated by signaling pathways downstream EGF that might involve
KRAS. However, similar to the effects seen in BxPC-3 cells, we could
confirm that knockdown of RSK3 significantly decreased cell viability
in PaTu-8988t cells (Figure W3).
RSK3 Is Expressed in Human and Murine Pancreatic Cancer
To assess RSK3 activation levels in pancreatic cancer tissues, we
performed immunohistochemical analysis of RSK3 on human and
murine paraffin-embedded pancreatic sections. Human tissue was
analyzed in an MTA comprising 548 tissue samples from 123 patients.
In 220 of 548 tissue samples (49 of 123 patients, 40%), we found high
signals after staining for pRSK3 (Thr353/Thr356), indicative for active
RSK3 (Figure 2B). Murine pancreatic tissues were obtained from the
KPC mouse model (LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx1-Cre),
which reliably recapitulates human pancreatic carcinogenesis on both
molecular and histologic level [18]. In pancreatic cancers derived from
this mouse model, strong signals of active RSK could be confirmed
(Figure 2C ).
RSK3 Protects Cells from Apoptosis
To functionally dissect the impact of RSK3 knockdown on cell
viability detected in the screen, we assessed its effect on cell prolifer-
ation and apoptosis.
Interestingly, knockdown of RSK3 had only a minor effect on cell
proliferation in the presence of erlotinib in both PaTu-8988t and
BxPC-3 cells, as assessed by BrdU assays (Figure W4). On the basis of
these assays, it appears that the effect on cell viability, as detected by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assays, is not mediated through modulation of cell proliferation.
Therefore, we examined the impact of RSK3 modulation on both
basal and drug-induced apoptosis. Knockdown of RSK3 in PaTu-
8988t cells significantly increased apoptosis in the presence of
Figure 2. RSK3 protein expression in pancreatic cancer. (A) RSK3 protein expression in various pancreatic cancer cell lines and the
pancreatic ductal epithelial cell line HPDE, as assessed by Western blot analysis. (B) Representative immunohistochemical analysis
of phospho-RSK3 (Thr356/Ser360) expression indicative of active RSK3 in human normal pancreatic tissue and pancreatic cancers.
(C) RSK3 expression in murine pancreatic cancer tissue derived from the KPC mouse model, as assessed by immunohistochemistry
using the phospho-RSK3 (Ser218) antibody.
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erlotinib. In the absence of erlotinib, however, apoptosis was un-
affected (Figure 3A), indicating a synergistic action between erlotinib
and RSK3 inhibition. Similar results were obtained in BxPC-3 cells
(Figure W5). Furthermore, we generated PaTu-8988t cells stably
overexpressing RSK3 to examine whether RSK3 expression is able
to rescue from drug-induced apoptosis (Figure 3B). RSK3 over-
expression resulted in a slight but nonsignificant reduction in apop-
tosis induced by erlotinib alone. However, when apoptosis was
induced by erlotinib in combination with the nucleoside analog
gemcitabine, which is commonly used in pancreatic cancer therapy,
or by gemcitabine alone, RSK3 completely abolished apoptosis
to baseline levels (Figure 3B). These data suggest that RSK3 over-
expression is able to rescue from drug-induced apoptosis and
inhibition of RSK3 acts synergistically with EGFR inhibition to
induce apoptosis.
RSK3 Activity Is Regulated by EGF/MEK/ERK Signaling
Several reports indicate that EGF-dependent signaling pathways
function as major activators of RSK proteins in various cell types
[19]. To examine the upstream activation pathways of RSK3 in pan-
creatic cancer cells, we incubated serum-starved PaTu-8988t and
BxPC-3 cells with recombinant EGF and examined phosphorylation
of RSK3 at residues Thr356/Ser360 and Ser218 with phospho-specific
antibodies. Phosphorylation of both residues was detected 5 to 10 min-
utes after addition of EGF, peaking at 15 minutes (Figure W6).
EGF-dependent signaling pathways are mediated through two main
downstream cascades involving the kinases MEK-ERK or
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-AKT. Phos-
phorylation at residue Thr356/Ser360 has been attributed to MEK/
ERK signaling, whereas Ser218 has been associated with phosphor-
ylation through 3′-phosphoinositide–dependent protein kinase-1
(PDK1), which, in addition, acts upstream of PI3K-AKT [11]. To
further elucidate the upstream signaling events involved in RSK3 acti-
vation, we coincubated EGF-activated BxPC-3 and PaTu-8988t cells
with erlotinib as well as the MEK inhibitor UO126 and the PI3K
inhibitor LY294002.
We could demonstrate that EGF induces phosphorylation of RSK3
at residues Thr356/Ser360 and Ser218, both of which could be reverted
by erlotinib (Figure 4A). MEK inhibition by UO126 abolished basal
and EGF-induced phosphorylation at residues Thr356/Ser360 but only
EGF-induced phosphorylation at Ser218, indicating that EGF-induced
phosphorylation at Ser218 involves MEK-dependent mechanisms but
basal phosphorylation occurs independently of MEK. PI3K inhibition
by LY294002 had no effect on RSK phosphorylation at either residue,
suggesting that PI3K/AKT signaling is not able to modulate RSK acti-
vation in these cell lines. Similar results were obtained in KRASmutated
PaTu-8988t (Figure 4A) andKRASwild-type BxPC-3 cells (Figure 4C).
To rule out cell line–dependent differences and to further investigate
the impact of constitutively active KRAS in RSK phosphorylation, we
generated BxPC-3 cells harboring a constitutively active KRAS. In these
cells, we detected elevated basal RSK3 phosphorylation levels at both
Thr356/Ser360 and Ser218, but EGF stimulation as well as inhibition
by erlotinib and UO126 was still effective (Figure 4C ). Both data in
PaTu-8988t and mutant KRAS–expressing BxPC-3 cells indicate that
EGF stimulation and downstream signaling to RSK3 is still active
despite the presence of a constitutively active KRAS protein.
rpS6 Is a Downstream Target for RSK3
On the basis of our functional data demonstrating a strong anti-
apoptotic phenotype induced by RSK3 after activation by EGF/MEK/
ERK signaling, we were interested in which downstream effectors
are employed by RSK3 to mediate its prosurvival effects. Reports
in various cell systems suggest several downstream effectors such
as 5' AMP-activated protein kinase α (AMPKα), a key regulator of
energy homeostasis, the tumor suppressor LKB1, and the rpS6 as
putative phosphorylation targets of RSK3. In pancreatic cancer cells,
we could not detect a consistent modulation of AMPKα and/or
LKB1 phosphorylation by RSK3 (data not shown). The rpS6, how-
ever, which has been linked to tumor cell growth and survival [20],
could be verified as target of RSK3 in pancreatic cancer cells: EGF-
induced RSK3 phosphorylation and its inhibition by erlotinib or
UO126 were accompanied by concordant phosphorylation patterns of
rpS6 in both PaTu-8988t (Figure 4B) and BxPC-3 cells with or with-
out KRAS mutation (Figure 4D). Furthermore, knockdown of RSK3
by siRNA markedly decreased phosphorylation of rpS6 (Figures 5A
and W7). In addition, we used the specific RSK inhibitor BI-D1870
Figure 3. RSK3 inhibition induces apoptosis synergistically with erlotinib, and RSK3 mediates resistance to apoptosis. (A) PaTu-8988t
cells were transiently transfected with siRNA against RSK3 (siRSK3) or siC and treated with erlotinib or solvent DMSO. siRSK3 sensitizes
PaTu-8988t cells to erlotinib treatment but is ineffective in the absence of erlotinib. (B) Clones stably overexpressing RSK3 or empty
vector were incubated with gemcitabine and/or erlotinib. Apoptosis was determined by a DNA fragmentation assay. *P < .05 compared
to siC (A) or Mock-transfected clones (B). Results are representative for three independent experiments.
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Figure 4. RSK3 is activated by EGF/EGFR through the MEK/ERK signaling cascade and modulates rpS6 phosphorylation. Serum-starved
cells were incubated with the EGFR inhibitor erlotinib, the MEK inhibitor UO126, or the PI3K inhibitor LY294002 for 2 hours before stim-
ulation with EGF for 15 minutes. Phosphorylation status of ERK and RSK3 (A) as well as rpS6 (B) was determined using specific antibodies
by Western blot analysis in PaTu-8988t cells harboring mutant KRAS. (C and D) BxPC-3 cells with wild-type KRAS (Mock) and BxPC-3 cells
stably transfected with constitutively active KRAS (KRAS) were incubated with the indicated compounds as above. Phosphorylation
status of ERK and RSK3 (C) as well as rpS6 (D) was determined using specific antibodies by Western blot analysis in BxPC-3 cells stably
expressing wild-type (Mock) or mutant KRAS (KRAS). Note that the PI3K inhibitor LY294002 has a profound impact on rpS6 phosphor-
ylation but not on RSK3 phosphorylation, suggesting that PI3K/mTOR signaling affects rpS6 phosphorylation independently of RSK3.
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that potently diminishes RSK3 activity but also affects other RSK iso-
forms [21]. Incubation with BI-D1870 decreased basal phosphorylation
of rpS6, as did the addition of erlotinib (Figures 5B and
W8). Simultaneous incubation with both BI-D1870 and erlotinib de-
creased rpS6 phosphorylation even further, indicating a syner-
gistic action of the RSK inhibitor BI-D1870 and the EGFR inhibitor
erlotinib in decreasing rpS6 activity (Figures 5B and W8). These
data indicate that rpS6 is phosphorylated by RSK3 in pancreatic cancer
cells and RSK inhibition and EGFR inhibition synergistically affect
rpS6 phosphorylation.
RSK Inhibition by BI-D1870 Acts Synergistically
with Erlotinib
In addition to our genetic screening approach, we were interested
in if pharmacological RSK inhibition using BI-D1870 is also acting
synergistically with erlotinib. A dose-response experiment revealed
that both BxPC-3 and PaTu-8988t cells were sensitive to BI-D1870.
PaTu-8988t cells, however, required an approximately 5× higher con-
centration to achieve a 50% reduction in cell viability (Figure W9).
Treatment of both PaTu-8988t and BxPC-3 cells with BI-D1870 in
the presence or absence of erlotinib resulted in a synergistic decrease of
cell viability after combined treatment (Figure 6).
As seen after RNAi-mediated knockdown of RSK3 in the presence
of erlotinib, pharmacological inhibition of RSK in the presence of
erlotinib resulted in a marked increase in apoptosis, determined by
PARP cleavage (Figures 7A and W10). Conversely, apoptosis induced
by BI-D1870 or by combined treatment with BI-D1870 and erloti-
nib was abolished by overexpression of RSK3 in stable clones of
PaTu-8988t cells (Figure 7B). This indicates that pharmacological
RSK inhibition and EGFR inhibition act together by inducing
apoptosis and RSK3 overexpression might confer resistance to drug-
induced apoptosis.
Discussion
In this study, we employed an RNAi-based loss-of-function screen to
identify mediators of tumor progression whose therapeutic inhibition
would act synergistically with the EGFR inhibitor erlotinib. We
identified the p90 S6 kinase RSK3 as potent mediator of resistance
to apoptosis whose genetic silencing or pharmacological inhibition
synergistically enhanced the effect of erlotinib. RSK3 is predomi-
nantly activated by EGF signaling through MEK/ERK-dependent
pathways, both in KRAS wild-type and KRAS mutated pancreatic
cancer cells. The rpS6 was identified as downstream target of RSK3
in pancreatic cancer cells, mediating its effects on tumor cell survival.
Increased expression of RSKs has been reported in several tumors
such as breast [22] and prostate cancers [23]. RSKs are also expressed
in pancreatic cancer cells, and their activation following EGF stimu-
lation has been shown to be dependent on MEK/ERK signaling [24].
So far, data on RSK expression levels in pancreatic cancer tissues
are missing. Our data in a large MTA indicate that RSK3 is expressed
in approximately 40% of pancreatic cancer tissues. Interestingly, our
expression data with pancreatic cancer cell lines harboring mutant or
wild-type KRAS indicate that the protein expression is regulated by
signaling pathways independent of KRAS.
Most functional data on RSK family members have been obtained
with RSK1 and RSK2 [11]. Reports on the functional effects of
Figure 6. Pharmacological inhibition of RSK3 acts synergistically with erlotinib. BxPC-3 (A) and PaTu-8988t (B) cells were treated with the
RSK inhibitor BI-D1870 in the presence or absence of erlotinib for 48 hours. Cell viability of cells was assessed using MTT assays.
Results are representative for three independent experiments. *P < .05 compared to erlotinib only and to erlotinib + BI-D (1 μM, A or
5 μM, B).
Figure 5. RSK3 phosphorylates rpS6. (A) PaTu-8988t cells were
transiently transfected with siRSK3 or siC at two different siRNA
concentrations (25 and 50 nM). Phosphorylated rpS6 and total
rpS6 were detected with specific antibodies. (B) PaTu-8988t cells
were treated with the RSK inhibitor BI-D1870 (5 μM) and/or erlotinib
(10 μM) for the indicated time points. Phospho-rpS6 and total rpS6
were detected by specific antibodies.
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RSK3 are limited. Generally, RSKs are known to promote cell cycle
progression through the regulation of mediators of the cell cycle,
e.g., by controlling the activity of p27 [11,25]. In addition, RSK1
and RSK2 were found to promote survival in various cell types,
e.g., by phosphorylation of the proapoptotic protein Bad, which
enhances its binding and inactivation by 14-3-3 proteins [26]. Fur-
thermore, RSK1 and RSK2 have been shown to phosphorylate and
thereby inactivate proapoptotic death-associated protein kinase
(DAPK), resulting in increased cell survival in response to mitogenic
stimulation [11,27].
The few reports on the putative role of RSK3 in cancer show the
following conflicting results: In malignant mesotheliomas, RSK3
activity has been shown to decrease on ERK2 inhibition [28]. In
breast cancer, v-erb-b2 avian erythroblastic leukemia viral onco-
gene homolog 2 (ERBB2) has been reported to activate RSK3 in a
membrane-associated complex together with the estrogen receptor
[12]. Both reports suggest a tumor-promoting role of RSK3. In con-
trast, Bignone et al. describe RSK3 as putative tumor suppressor with
reduced expression in ovarian cancer and show that RSK3 over-
expression is associated with reduced proliferation and increased
apoptosis in ovarian cancer cell lines [13]. Our data based on both
genetic and pharmacological inhibition as well as overexpression
experiments clearly indicate that RSK3 plays a tumor-promoting role
and acts as strong mediator of survival and resistance to drug-induced
apoptosis in pancreatic cancer. The reasons for these discrepant
findings remain to be elucidated. Different epigenetic methylation
patterns might be responsible for the varying expression patterns.
Furthermore, the different RSK3 isoforms detected in the ovarian
cancer cell lines [13] may explain some of the functional differ-
ences. It appears evident that the role of RSK3 is cell type and con-
text dependent.
RSKs are known to be activated by EGF-dependent pathways
through MEK/ERK [11,29]. Therefore, at first glance, it appears
surprising that RSK inhibition acts synergistically with the EGFR
inhibitor erlotinib, because both EGFR and MEK/ERK signal within
one major pathway. Moreover, this synergism appears to be functional
in both KRAS wild-type and KRAS mutant cells. On the basis of our
data, it is likely that RSKs are activated by several EGFR-dependent
mechanisms, among themKRAS-dependent, but alsoKRAS-independent
complementary oncogenic signaling pathways. Recent reports in pan-
creatic cancer cell lines and genetic mouse models corroborate this
hypothesis: In vitro, the unique activities of EGFR have been shown
to promote cell proliferation and invasion even when KRAS is mutated
[30,31]. In vivo, genetic ablation or pharmacological inhibition of
EGFR by erlotinib effectively eliminated KRAS-driven tumorigenesis
in a mouse model of pancreatic cancer. Without EGFR activity, KRAS
was not sufficient to induce robust MEK/ERK activity. In addition,
EGFR activity was required for acinar-ductal metaplasia [32]. More-
over, active KRAS has been shown to induce EGFR expression, which
underlines the complex interplay between KRAS and EGFR signaling
and provides an additional rational for EGFR inhibition even in the
presence of mutated KRAS. Our data indicate that RSK3 activity is
induced by EGFR signaling through substantial amplification of MEK-
ERK activation through KRAS-dependent and KRAS-independent
pathways. The exact mechanisms of KRAS-independent MEK-ERK
activation leading to subsequent RSK induction remain to be elucidated.
Phosphorylation of RSK3 at Thr356/Ser360 has been associated with
ERK activity. In contrast, Ser218 is phosphorylated by PDK1 [11].
We could show that MEK inhibition by UO126 abolished basal and
EGF-induced phosphorylation at residues Thr356/Ser360 and EGF-
induced phosphorylation at Ser218. This is consistent with the notion
that phosphorylation by ERK creates a docking site for PDK1 that, in
turn, phosphorylates Ser218 in the activation loop [11]. The PI3K inhib-
itor LY294002 had no effect on either phosphorylation site, indicating
that PI3K/Akt signaling, which represents an additional downstream
target of PDK1, is not involved in activation of RSK3.
Numerous downstream targets of RSKs have been described, most
of them for RSK1 and RSK2. The rpS6 represents one of these
targets and plays a crucial role within the translation machinery as
component of the 40S ribosomal subunit [33]. rpS6 is phosphory-
lated by RSKs at Ser235/236 in vitro and in vivo through mechanistic
target of rapamycin (mTOR)-independent mechanisms. Our data
provide evidence that rpS6 represents a crucial downstream target
of RSK3 mediating at least partly its effects on tumor cell survival.
In addition to its role in enhancing protein translation, several
reports confirm that rpS6 is important for cell survival [20]. Interest-
ingly, rpS6 has been identified as target in an siRNA-based synthetic
lethal screen for modifiers of insulin-like growth factor 1 receptor
Figure 7. Synergistic effect of RSK inhibition by BI-D1870 and EGFR inhibition by erlotinib. (A) PaTu-8988t cells were treated with BI-D1870
(5 μM) and/or erlotinib (10 μM), and PARP cleavage was determined by Western blot analysis after 24 hours. (B) PaTu-8988t cells stably
overexpressing RSK3 or empty vector (Mock) were treated with BI-D1870 and/or erlotinib, and apoptosis was determined by DNA frag-
mentation assays. *P < .05 compared to either Mock clone. Data are representative for three independent experiments.
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(IGF1R) kinase inhibitor activity in sarcomas [20]. In this report, an
IGF1R kinase inhibitor failed to block rpS6 activation in resistant
sarcoma cell lines, indicating that rpS6 represents an important
mediator of resistance to IGF1R inhibition and therefore a potential
target for the implementation of synergistically acting inhibitor
strategies [20].
Our data clearly indicate that RSK inhibition and EGFR inhibi-
tion is synthetically lethal in pancreatic cancer cells. In contrast to
erlotinib that is used routinely in patients, available RSK inhibitors
are limited to in vitro use so far, mainly due to solubility restrictions.
On the basis of our data, the development of novel RSK inhibitors or
the chemical modification of existing RSK inhibitors are warranted
and currently ongoing in our laboratory. This will facilitate the in vivo
evaluation of simultaneous RSK- and EGFR-targeting strategies in
preclinical trials using genetic mouse models of pancreatic cancer as
well as clinical trials that hopefully will be able to improve the devas-
tating prognosis and therapy resistance of pancreatic cancer.
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